Declining eyesight improved by looking at deep red light
Staring at a deep red light for three minutes a day can significantly improve declining eyesight, finds a new UCL-led study, the first of its kind in humans.
Scientists believe the discovery, published in the Journals of Gerontology, could signal the dawn of new affordable home-based eye therapies, helping the millions of people globally with naturally declining vision.
In the UK there are currently around 12 million people aged over 65: in 50 years this will increase to around 20 million and all will have some degree of visual decline because of retinal ageing.
Lead author, Professor Glen Jeffery (UCL Institute of Ophthalmology) said: “As you age your visual system declines significantly, particularly once over 40.
“Your retinal sensitivity and your colour vision are both gradually undermined, and with an ageing population, this is an increasingly important issue.
“To try to stem or reverse this decline, we sought to reboot the retina’s ageing cells with short bursts of longwave light.”
In humans around 40 years-old, cells in the eye’s retina begin to age, and the pace of this ageing is caused, in part, when the cell’s mitochondria, whose role is to produce energy (known as ATP) and boost cell function, also start to decline.
Mitochondrial density is greatest in the retina’s photoreceptor cells, which have high energy demands. As a result, the retina ages faster than other organs, with a 70% ATP reduction over life, causing a significant decline in photoreceptor function as they lack the energy to perform their normal role.
Researchers built on their previous findings in mice, bumblebees and fruit flies, which all found significant improvements in the function of the retina’s photoreceptors when their eyes were exposed to 670 nanometre (long wavelength) deep red light.
“Mitochondria have specific light absorbance characteristics influencing their performance: longer wavelengths spanning 650 to 1000nm are absorbed and improve mitochondrial performance to increase energy production,” said Professor Jeffery.
The retina’s photoreceptor population is formed of cones, which mediate colour vision and rods, which provide peripheral vision and adapt vision in low/dim light.
For the study, 24 people (12 male, 12 female), aged between 28 and 72, who had no ocular disease, were recruited. All participants’ eyes were tested for the sensitivity of their rods and cones at the start of the study. Rod sensitivity was measured in dark adapted eyes (with pupils dilated) by asking participants to detect dim light signals in the dark, and cone function was tested by subjects identifying coloured letters that had very low contrast and appeared increasingly blurred, a process called colour contrast.
All participants were then given a small LED torch to take home and were asked to look into* its deep red 670nm light beam for three minutes a day for two weeks. They were then re-tested for their rod and cone sensitivity
Researchers found the 670nm light had no impact in younger individuals, but in those around 40 years and over, significant improvements were obtained.
Cone colour contrast sensitivity (the ability to detect colours) improved by up to 20% in some people aged around 40 and over. Improvements were more significant in the blue part of the colour spectrum that is more vulnerable in ageing.
Rod sensitivity (the ability to see in low light) also improved significantly in those aged around 40 and over, though less than colour contrast.
Professor Jeffery said: “Our study shows that it is possible to significantly improve vision that has declined in aged individuals using simple brief exposures to light wavelengths that recharge the energy system that has declined in the retina cells, rather like re-charging a battery.
“The technology is simple and very safe, using a deep red light of a specific wavelength, that is absorbed by mitochondria in the retina that supply energy for cellular function.
“Our devices cost about £12 to make, so the technology is highly accessible to members of the public.”
This research was funded by the Biotechnology and Biological Sciences Research Council.
*Participants placed their eye over the end of the torch. Eyes could be closed as the red light is not filtered by the eye lid.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- 'Cautiously optimistic' | Data scientists shift more focus to variants as COVID-19 trends decline in North Carolinaon February 24, 2021 at 10:58 am
GREENSBORO, N.C. — As COVID-19 trends continue to decline across North Carolina, data scientists are still keeping a close eye on information to best prepare for the future. Cone Health pushed its ...
- High-Performing Culture Through the Eyes of Your Customerson February 24, 2021 at 10:24 am
One would think that fewer companies would mean less competition, but the opposite is true. The competitive nature of the industry is stronger than ever. Competitors are increasingly upping their game ...
- Groups eye shipping industry for Basel enforcementon February 24, 2021 at 9:46 am
Activists have contacted the world’s largest shipping lines, asking them to stop carrying shipments that violate new Basel Convention regulations covering the global scrap plastic trade. Numerous ...
- Diabetic Eye Disease Devices Market Trends,Share Manufacturers, Type, Application, Export, Import and Regions Analysis Till 2027on February 24, 2021 at 6:14 am
USA Oregon Portland Published Latest Report titled Diabetic Eye Disease Devices Market Global Opportunity Analysis and Industry Forecast 2020 2027 The Diabetic Eye Disease Devices Market is expected ...
- Regulators keep close eye on Facebook's deal with Australiaon February 24, 2021 at 3:00 am
Facebook and Australia’s eleventh-hour agreement Monday letting users resume sharing news links on the platform is being closely watched by regulators around the world as a possible model for ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Home-based eye therapies
- Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Callon February 18, 2021 at 6:10 am
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced ...
- DCYF seeking bids to help revamp child-protective serviceson February 16, 2021 at 7:51 pm
With MST in place, DCYF will place less emphasis on Home Based Therapy, which involved counselors visiting homes but not following a specific therapeutic model, he said. Savings in Home Based ...
- Parkinson's Research Newson February 15, 2021 at 3:59 pm
Feb. 4, 2021 — Ultrasound is not only used as an imaging technique but targeted pulses of ultrasound can be used as a highly accurate treatment ... 2020 — A simple eye exam combined with ...
- New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney canceron February 15, 2021 at 7:58 am
New data for Merck & Co (MSD) and Eisai’s Keytruda plus Lenvima combination treatment has demonstrated further promise for the therapy in advanced renal cell carcinoma (RCC) – the most common form of ...
- Roche’s vision loss therapy faricimab extends time between treatments by up to four monthson February 12, 2021 at 4:37 am
Roche added that faricimab is the first injectable eye medicine to achieve this length of time between treatments in Phase III studies for DME and nAMD. “These positive results show the potential for ...